- Home
- TNYA vs SLS Comparison
TNYA vs SLS Comparison
Compare TNYA & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TNYA | SLS |
|---|---|---|
| Founded | 2016 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 234.8M | 208.0M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | TNYA | SLS |
|---|---|---|
| Price | $1.44 | $1.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $8.60 | $7.00 |
| AVG Volume (30 Days) | 2.0M | ★ 4.3M |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.36 | $0.77 |
| 52 Week High | $4.01 | $2.48 |
Technical Indicators
Market Signals| Indicator | TNYA | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 52.21 | 61.34 |
| Support Level | $1.34 | $1.39 |
| Resistance Level | $1.43 | $2.00 |
| Average True Range (ATR) | 0.10 | 0.14 |
| MACD | 0.03 | 0.06 |
| Stochastic Oscillator | 86.67 | 81.97 |
Price Performance
Historical ComparisonAbout TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.